Abstract
Expression of urokinase- and tissue-type plasminogen activators and their inhibitor PAI-1 in the cytosolic fraction of 20 osteosarcomas, 20 chondrosarcomas, 13 giant-cell bone tumors, 5 Ewing's sarcomas, and 7 osteochondral exostoses was studied by enzyme immunoassay. The content of urokinase-type plasminogen activator increased, while the concentration of tissue-type plasminogen activator decreased in bone tumors of various histological compositions compared to osteochondral exostoses. A positive correlation was found between PAI-1 content and the volume of osteo- and chondrosarcomas. Expression of urokinase-type plasminogen activator increased in patients with primary osteosarcomas characterized by early generalization of the pathological process.
MeSH terms
-
Adolescent
-
Adult
-
Bone Neoplasms / enzymology*
-
Bone Neoplasms / metabolism
-
Bone Neoplasms / pathology*
-
Child
-
Chondrosarcoma / enzymology
-
Chondrosarcoma / metabolism
-
Chondrosarcoma / pathology
-
Cytosol / enzymology
-
Cytosol / metabolism
-
Female
-
Giant Cell Tumor of Bone / enzymology
-
Giant Cell Tumor of Bone / metabolism
-
Giant Cell Tumor of Bone / pathology
-
Humans
-
Male
-
Middle Aged
-
Osteochondroma / enzymology
-
Osteochondroma / metabolism
-
Osteochondroma / pathology
-
Osteosarcoma / enzymology
-
Osteosarcoma / metabolism
-
Osteosarcoma / pathology
-
Plasminogen Activator Inhibitor 1 / metabolism*
-
Plasminogen Activators / metabolism*
-
Sarcoma, Ewing / enzymology
-
Sarcoma, Ewing / metabolism
-
Sarcoma, Ewing / pathology
-
Tissue Plasminogen Activator / metabolism
-
Urokinase-Type Plasminogen Activator / metabolism
Substances
-
Plasminogen Activator Inhibitor 1
-
Plasminogen Activators
-
Tissue Plasminogen Activator
-
Urokinase-Type Plasminogen Activator